echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > GUT: Hypophosphatemia occurs in patients with iron deficiency anemia due to inflammatory bowel disease after taking ferric isomaltose

    GUT: Hypophosphatemia occurs in patients with iron deficiency anemia due to inflammatory bowel disease after taking ferric isomaltose

    • Last Update: 2023-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Anemia is the most common extraintestinal manifestation of inflammatory bowel disease (IBD), with iron deficiency and inflammation being the main causes
    .
    IBD-associated anemia (iron deficiency and anemia of chronic disease) is associated with
    impaired physical and cognitive function, increased hospitalization, and reduced quality of life.
    The European Crohn's Disease and Colitis Organization (ECCO) recommends high-dose intravenous iron as first-line treatment for iron deficiency anaemia (IDA) in IBD patients, as the bioavailability and efficacy of oral iron are limited
    in patients with inflammation.
    Iron isomaltose (FDI; Formerly known as iron isomaltoside) and iron carboxymaltose (FCM), they are the most widely used intravenous iron agents in Europe
    .
    Hypophosphatemia is increasingly recognized as an important side effect
    of some intravenous iron preparations.
    Hypophosphatemia due to intravenous iron infusion most commonly occurs in the first 2 weeks after infusion and can be mild and asymptomatic, but in some cases can be severe, symptomatic, persistent, and associated with alterations in mineral and bone metabolism that ultimately lead to osteomalacia and fractures
    .

    To compare the incidence
    of hypophosphatemia after treatment with ferric carboxymaltose (FCM) or ferric isomaltose (FDI).

    This randomized, double-blind clinical trial was conducted in 20 outpatient hospitals in
    Europe.
    The researchers randomized adults with IBD and iron deficiency anemia (IDA) to receive FCM or FDI in a 1:1 ratio at baseline and day 35, followed by the same hemoglobin and weight-based dosing regimen
    .
    The primary outcome to be observed was the incidence of hypophosphatemia (serum phosphate <2.
    0 mg/dL) at any time from baseline to day 35 in safety analysis (all patients receiving ≥1 dose of study drug
    ).
    Markers of mineral and bone homeostasis, as well as patient-reported fatigue scores
    , were measured.

    A total of 156 patients were screened in this study; Ninety-seven (49 FDI, 48 FCM) were included in the analysis
    .
    The results showed hypophosphatemia (HR: -42.
    8% (95% CI –57.
    1% to –24.
    6%) p< 0.
    0001) in 8.
    3% (4/48) of patients treated with FDI and 51.
    0% (25/49) of patients treated with FCM
    .
    Both iron preparations correct IDA
    .
    Patient-reported fatigue scores improved in both groups, but FCM was slower and less severe than FDI; Slower improvement in fatigue is associated with
    a greater decrease in phosphate concentration.

    This study confirms that the incidence of hypophosphatemia due to FCM is significantly higher than that of FDI,
    despite the comparable therapeutic efficacy of IDA.
    Further research is needed to support the mechanisms
    by which FCM and FDI differ in their effects on patient-reported fatigue.

     

    Original source:

    Heinz Zoller.
    et al.
    Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    GUT.
    2022.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.